Formulation and Evaluation of Transdermal patches of Ropinirole HCl

Abstract

ABSTRACT The conventional multidose antiparkinsons therapy leads to re-emergence of Parkinson's symptoms, due to fluctuations in serum levels of drug. The rational strategy to overcome this drawback is to minimize the fluctuations by fabricating sustained release formulations. Ropinirole HCl is a drug used to treat Parkinson's disorder and it is suitable drug candidate for transdermal delivery due to its small molecular size, optimum log P and low oral bioavailability due to first pass metabolism. Hence the present study was aimed at development of transdermal patch of Ropinirole HCl to show its prolonged release. The combination of HPMC K15 and Eudragit RL100 was tried as a porous matrix to control the release of Ropinirole HCl up to 12 hrs. The transdermal patches were prepared by solvent casting method. All the patches were evaluated for the permeation along with physical studies including appearance, thickness, folding endurance, drug content, percentage of moisture content and percentage of moisture uptake. The results of physical parameters ensured integrity, stability and applicability of the patches. The results of permeation studies clearly indicated that the release pattern of Ropinirole HCl can be controlled by maintaining appropriate proportion of HPMC K15 and Eudragit RL 100 in the matrix. No erythma was found within 12 hr after application of optimized transdermal patch when compared with standard irritant. Thus this formulation was suitable for transdermal application